Literature DB >> 68402

Lithium in acute myeloid leukaemia.

D Charron, A J Barrett, A Faille, N Alby, T Schmitt, L Degos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 68402     DOI： 10.1016/s0140-6736(77)91339-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Biological response modifiers and differentiation inducers. Current status in cancer research.

Authors:  P Reizenstein; G Mathé
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

2.  Haematological effects of lithium and its use in treatment of neutropenia.

Authors:  A J Barrett
Journal:  Blut       Date:  1980-01

3.  Double-blind, placebo-controlled lithium treatment in chemotherapy induced aplasia for AML: reduced antibiotic requirement.

Authors:  S Collado; D Charron; L Degos
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Authors:  Versha Banerji; Stacey M Frumm; Kenneth N Ross; Loretta S Li; Anna C Schinzel; Cynthia K Hahn; Rose M Kakoza; Kwan T Chow; Linda Ross; Gabriela Alexe; Nicola Tolliday; Haig Inguilizian; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Giovanni Roti; Jon C Aster; William C Hahn; Andrew L Kung; Kimberly Stegmaier
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

5.  Influence of lithium and fluoride on degranulation from human neutrophils in vitro.

Authors:  F J Bloomfield; M M Young
Journal:  Inflammation       Date:  1982-09       Impact factor: 4.092

6.  Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.

Authors:  Brent M Kuenzi; Lily L Remsing Rix; Fumi Kinose; Jodi L Kroeger; Jeffrey E Lancet; Eric Padron; Uwe Rix
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.